New NSCLC patients generally undergo CLIA certified tumor mutation analysis to help guide therapy and some diagnostic oncology panels such as Foundation One already include STK11 mutations (www.foundationmedicineasia.com/content/dam/rfm/apac_v2-en/FOne_Current_Gene_List.pdf). The gene discussed is STK11; the disease is neoplasm.